Literature DB >> 24965976

The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs).

Eleni Bili, Authors Eleni Bili1, Kaliopi Dampala2, Ioannis Iakovou3, Dimitrios Tsolakidis2, Anastasia Giannakou4, Basil C Tarlatzis2.   

Abstract

OBJECTIVES: The aim of this study was to determine the performance of prostate specific antigen (PSA) and ultrasound parameters, such as ovarian volume and outline, in the diagnosis of polycystic ovary syndrome (PCOS). STUDY
DESIGN: This prospective, observational, case-controlled study included 43 women with PCOS, and 40 controls. Between day 3 and 5 of the menstrual cycle, fasting serum samples were collected and transvaginal ultrasound was performed. The diagnostic performance of each parameter [total PSA (tPSA), total-to-free PSA ratio (tPSA:fPSA), ovarian volume, ovarian outline] was estimated by means of receiver operating characteristic (ROC) analysis, along with area under the curve (AUC), threshold, sensitivity, specificity as well as positive (+) and negative (-) likelihood ratios (LRs). Multivariate logistical regression models, using ovarian volume and ovarian outline, were constructed.
RESULTS: The tPSA and tPSA:fPSA ratio resulted in AUC of 0.74 and 0.70, respectively, with moderate specificity/sensitivity and insufficient LR+/- values. In the multivariate logistic regression model, the combination of ovarian volume and outline had a sensitivity of 97.7% and a specificity of 97.5% in the diagnosis of PCOS, with +LR and -LR values of 39.1 and 0.02, respectively.
CONCLUSIONS: In women with PCOS, tPSA and tPSA:fPSA ratio have similar diagnostic performance. The use of a multivariate logistic regression model, incorporating ovarian volume and outline, offers very good diagnostic accuracy in distinguishing women with PCOS patients from controls.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Diagnostic performance; Hyperandrogenemia; Polycystic ovary syndrome; Prostate specific antigen; Transvaginal ultrasound

Mesh:

Substances:

Year:  2014        PMID: 24965976     DOI: 10.1016/j.ejogrb.2014.05.006

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS).

Authors:  Eleftherios P Diamandis; Frank Z Stanczyk; Sarah Wheeler; Anu Mathew; Martin Stengelin; Galina Nikolenko; Eli N Glezer; Marshall D Brown; Yingye Zheng; Yen-Hao Chen; Hsiao-Li Wu; Ricardo Azziz
Journal:  Clin Chem Lab Med       Date:  2017-10-26       Impact factor: 3.694

2.  Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women.

Authors:  Emma Eklund; Eleftherios P Diamandis; Carla Muytjens; Sarah Wheeler; Anu Mathew; Martin Stengelin; Eli Glezer; Galina Nikolenko; Marshall D Brown; Yingye Zheng; Angelica Lindén Hirschberg
Journal:  F1000Res       Date:  2017-07-17

Review 3.  Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.

Authors:  Zeng-Hong Wu; Yun Tang; Xun Niu; Fei-Fei Pu; Xi-Yue Xiao; Wen Kong
Journal:  J Ovarian Res       Date:  2019-10-15       Impact factor: 4.234

4.  Genome-wide association study for SNPs associated with PCOS in human patients.

Authors:  Li Chen; Ling-Min Hu; Yu-Feng Wang; Hai-Yan Yang; Xiao-Yang Huang; Wei Zhou; Hai-Xiang Sun
Journal:  Exp Ther Med       Date:  2017-09-07       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.